A Phase 2b clinical trial designed to evaluate the efficacy and tolerability of multiple monthly doses of MET-097i after multiple weekly doses with and without titration
Latest Information Update: 02 Apr 2025
At a glance
- Drugs MET 097 (Primary)
- Indications Metabolic disorders; Obesity
- Focus Therapeutic Use
- Acronyms VESPER-3
- 02 Apr 2025 New trial record
- 26 Mar 2025 According to Metsera media release , Preliminary results are expected by year-end 2025 or early 2026